NCT02011347

Brief Summary

The objective is to evaluate the sparing effect of ketamine on the dose of propofol.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
67

participants targeted

Target at below P25 for phase_3

Timeline
Completed

Started Jul 2013

Geographic Reach
1 country

2 active sites

Status
terminated

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

July 1, 2013

Completed
5 months until next milestone

First Submitted

Initial submission to the registry

December 3, 2013

Completed
10 days until next milestone

First Posted

Study publicly available on registry

December 13, 2013

Completed
1.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 7, 2015

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

October 7, 2015

Completed
Last Updated

April 6, 2017

Status Verified

April 1, 2017

Enrollment Period

2.3 years

First QC Date

December 3, 2013

Last Update Submit

April 5, 2017

Conditions

Outcome Measures

Primary Outcomes (1)

  • administered dose of propofol during maintenance of anesthesia

    day 1

Secondary Outcomes (10)

  • bispectral index measurement

    1 day

  • administered dose of propofol during induction of anesthesia

    day 1

  • administered doses of remifentanil during induction and maintenance of anesthesia

    day 1

  • delay (measured as minutes) between the end of propofol and remifentanil administration and the recovery from anesthesia

    day 1

  • hemodynamic abnormalities requiring treatment

    day 1

  • +5 more secondary outcomes

Study Arms (2)

Ketamine

EXPERIMENTAL

Patients will receive a closed-loop administration of propofol and remifentanil according to bispectral level and Ketamine (bolus dose of Ketamine (0.15 mg.kg-1) followed by an infusion of Ketamine (0.15 mg.kg-1 h-1) until the end of anesthesia)

Drug: Ketamine

Placebo

EXPERIMENTAL

patients will receive a closed-loop administration of propofol and remifentanil according to bispectral level and a placebo (NaCl 9/00 (same volume as in the Ketamine group)

Drug: Placebo

Interventions

Ketamine
Placebo

Eligibility Criteria

Age18 Years - 65 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • patients with an American Society of Anesthesiology score 1, 2 or 3
  • scheduled for a surgical procedure lasting more than 2 hours under general anesthesia

You may not qualify if:

  • pregnancy
  • chronic pain
  • simultaneous general and loco-regional anesthesia
  • contra-indication to to nonsteroidal anti-inflammatory drug
  • contra-indication to Ketamine
  • contra-indication to propofol, to remifentanil, to morphine
  • history of central nervous system disease
  • patients receiving a psychotropic treatment
  • patients with a pace-maker

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

Hopital Foch

Suresnes, Hauts de Seine, 92151, France

Location

Clinique Fontaine les Dijons

Fontaine-lès-Dijon, 21121, France

Location

MeSH Terms

Interventions

Ketamine

Intervention Hierarchy (Ancestors)

CyclohexanesCycloparaffinsHydrocarbons, AlicyclicHydrocarbons, CyclicHydrocarbonsOrganic Chemicals

Study Officials

  • Marc Fischler, MD

    Hôpital Foch

    STUDY CHAIR

Study Design

Study Type
interventional
Phase
phase 3
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, CARE PROVIDER
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

December 3, 2013

First Posted

December 13, 2013

Study Start

July 1, 2013

Primary Completion

October 7, 2015

Study Completion

October 7, 2015

Last Updated

April 6, 2017

Record last verified: 2017-04

Locations